Long‐term benefits of single‐dose psilocybin in depressed patients with cancer
Cancer June 15, 2025 Manish Agrawal, Kim Roddy, Betsy Jenkins et al. 4 citations
A single 25 mg dose of psilocybin combined with psychotherapy provided long-term relief from depression and anxiety in patients with cancer. Two years after treatment, over half of the 28 patients showed significant reduction in depression, with an average 15-point drop on the Montgomery Asberg Depression Rating Scale, and half maintained that improvement. Nearly half also experienced significant anxiety reduction, averaging a 13.9-point decrease on the Hamilton Anxiety Rating Scale, with 43% sustaining the benefit. The findings indicate a potentially paradigm-changing alternative to standard antidepressants for this population.